Pulmonary Fibrosis Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Pulmonary Fibrosis stocks.

Pulmonary Fibrosis Stocks Recent News

Date Stock Title
Jun 14 BIIB Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
Jun 14 BIIB The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
Jun 13 BIIB The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune
Jun 12 BIIB Biogen Inc. (BIIB) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
Jun 12 BIIB Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab
Jun 11 BIIB Eli Lilly Seesaws On FDA Win, And Pushes Alzheimer's Stocks Prothena, Eisai Lower
Jun 11 BIIB FDA Advisers Like Lilly’s Alzheimer’s Drug. It’s Good News for Biogen.
Jun 11 BIIB Eli Lilly (LLY) Alzheimer's Drug Donanemab Gets FDA Panel Nod
Jun 11 BIIB Donanemab approval would fuel growth of amyloid-blocking Alzheimer’s drugs, analysts say
Jun 11 BIIB Why Is Eli Lilly Stock Trading Higher Premarket Tuesday?
Jun 11 VCYT Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness
Jun 10 BIIB FDA panel votes unanimously for Eli Lilly's Alzheimer's treatment
Jun 10 BIIB Biogen, Eisai get January 2025 FDA action date for monthly Leqembi
Jun 10 BIIB Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug
Jun 10 BIIB Biogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance
Jun 9 BIIB FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Pulmonary Fibrosis

Pulmonary fibrosis is a condition in which the lungs become scarred over time. Symptoms include shortness of breath, a dry cough, feeling tired, weight loss, and nail clubbing. Complications may include pulmonary hypertension, respiratory failure, pneumothorax, and lung cancer.Causes include environmental pollution, certain medications, connective tissue diseases, infections (including SARS infections), interstitial lung diseases. Idiopathic pulmonary fibrosis (IPF), an interstitial lung disease of unknown cause, is most common. Diagnosis may be based on symptoms, medical imaging, lung biopsy, and lung function tests.There is no cure and there are limited treatment options available. Treatment is directed towards efforts to improve symptoms and may include oxygen therapy and pulmonary rehabilitation. Certain medications may be used to try to slow the worsening of scarring. Lung transplantation may occasionally be an option. At least 5 million people are affected globally. Life expectancy is generally less than five years.

Browse All Tags